Centaurus Financial’s Cardiff Oncology CRDF Stock Holding History

Centaurus Financial’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-33	Closed	–	–	818
2018 Q2	$0	Buy	+33	New	+$552	﹤0.01%	2249

Other funds holding CRDF

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Elkhorn Partners Omaha, Nebraska $117M AUM 28.12% 1-Year Est. Return

Dowling & Yahnke San Diego, California $2.15B AUM 10.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

SNB

Security National Bank Omaha, Nebraska $838M AUM 39.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Centaurus Financial's CRDF Position: Q3 2018 in Review

Centaurus Financial sold out of Cardiff Oncology (CRDF) in Q3 2018, closing a stake of 33 shares.

Centaurus Financial first reported a position in CRDF in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 33 funds tracked by Wall St. Rank hold CRDF as of Q3 2018.

Centaurus Financial reported no remaining Cardiff Oncology position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 33 Cardiff Oncology shares in Q3 2018.
Centaurus Financial first reported a position in Cardiff Oncology in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Cardiff Oncology position peaked at $0 in Q2 2018.
33 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.